Institut Jules Bordet

Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

BackgroundSavolitinib is an oral, potent, highly selective MET–tyrosine kinase inhibitor (TKI). Combination therapy with savolitinib and osimertinib, an epidermal growth factor receptor (EGFR)–TKI, has shown activity in patients with EGFR-mutated, advanced non–small-cell lung can...

Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer

Circulating tumor DNA (ctDNA)-based Minimal Residual Disease (MRD) assays are increasingly utilised in early-stage breast cancer; but evidence for decision-making remains incomplete. The Breast International Group (BIG) and National Clinical Trials Network (NCTN) ctDNA working gr...

Line‐Field Confocal Optical Coherence Tomography: A Diagnostic Tool Facilitating the Diagnosis of Sweet's Syndrome. A Case Report

ABSTRACT Sweet's syndrome is a rare neutrophilic dermatosis characterized by an acute onset of erythematous and infiltrative lesions. Diagnosis is based on clinical, histopathological, and laboratory findings. We propose that non‐invasive skin imaging techniques, such as line‐fie...

StereoBed - salvage stereotactic body radiotherapy of the prostate bed for biochemical recurrence after radical prostatectomy: study protocol for a randomized phase II/III trial

In cases of biochemical recurrence (BCR) after radical prostatectomy, salvage radiotherapy (RT) is a well-established standard-of-care treatment. Stereotactic body radiotherapy (SBRT) may offer a shorter treatment duration and favorable radiobiological characteristics, but eviden...

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

PURPOSE: Treatment options for progression on first-line endocrine therapy (ET)+CDK4/6i for ER-positive/HER2-negative (ER+/HER2-) advanced breast cancer (ABC) include ET plus targeted agents (CDK4/6i or PI3K/AKT/mTOR-pathway inhibitors). Elacestrant is the first single-agent oral...